Belsomra Tablet, Film Coated
Product Images NDC 0006-0325

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Belsomra (NDC 0006-0325). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Belsomra 01)

Chemical structure of suvorexant, the active ingredient in BELSOMRA, shown as a detailed molecular diagram with labeled ring structures and atoms including chlorine and nitrogen heterocycles.*

FDA Label Image

Figure 1 (Belsomra 02)

A pharmacokinetic interaction chart showing the effect of CYP3A inhibitors and inducers on suvorexant exposure. The chart compares mean changes and 90% confidence intervals for AUC and Cmax relative to reference for ketoconazole 400 mg, diltiazem 240 mg, and rifampin 600 mg, with corresponding dosing recommendations.*

FDA Label Image

Figure 2 (Belsomra 03)

A chart showing the mean effect and 90% confidence interval of various interacting drugs on pharmacokinetic parameters, including AUC and Cmax, relative to a reference. It lists interacting drugs such as Midazolam, Warfarin enantiomers, Digoxin, and combined oral contraceptives, alongside recommendations indicating no dose adjustments are needed. The x-axis represents change relative to reference.*

FDA Label Image

Principal Display Panel (5 mg Tablet Blister Card Case Carton)

BELSOMRA 5 mg (suvorexant) film-coated tablets packaging label. The label shows the product name, strength, and dosage form, with instructions to dispense the medication guide. Each package contains 30 tablets in 3 blister cards of 10 tablets each. Manufactured by Merck Sharp & Dohme LLC, it includes storage instructions, a toll-free number, and a website for more information.*

FDA Label Image

Principal Display Panel (10 mg Tablet Blister Card Case Carton)

Packaging label for BELSOMRA (suvorexant) tablets 10 mg film-coated oral tablets. The label states the product strength as 10 mg and includes the Merck Sharp & Dohme LLC labeler information. The package contains 30 tablets in 3 blister cards. Storage instructions and legal warnings are also visible. The design features a colored wave motif along the right side.*

FDA Label Image

Principal Display Panel (15 mg Tablet Blister Card Case Carton)

Packaging label for BELSOMRA 15 mg film-coated tablets (suvorexant), a human prescription drug manufactured by Merck Sharp & Dohme LLC. The label includes dosage form, strength, and instructions about the packaging containing 30 tablets in 3 blister cards. The design features the product name prominently with purple accents and regulatory information.*

FDA Label Image

Principal Display Panel (20 mg Tablet Blister Card Case Carton)

BELSOMRA 20 mg suvorexant tablets packaging label. The label shows a box design for a 30-tablet supply, with tablets divided across 3 blister cards of 10 tablets each. It includes the Merck Sharp & Dohme LLC logo and contact information, storage instructions, and legal dispensing warnings. The dosage form is film-coated tablets for oral use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.